Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal groups A, B, C, W and Y vaccine
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Meningococcal groups A, B, C, W and Y vaccine** is a pentavalent conjugate vaccine that provides active immunization against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y. It combines quadrivalent MenACWY components (polysaccharides from serogroups A, C, W, Y conjugated to tetanus toxoid or CRM197) with recombinant proteins targeting serogroup B (fHBP variants), administered as a single 0.5 mL intramuscular dose to individuals aged 10 years and older, including those at increased risk such as during outbreaks, with asplenia, complement deficiencies, HIV, or complement inhibitor use. Developed by Pfizer, it offers a convenient single-shot alternative to separate MenACWY and MenB vaccines, with routine recommendations for adolescents and boosters for ongoing risk.[4][16][22]
- Brand names
- Penbraya
- Other names
- MenABCWY vaccinepentavalent meningococcal vaccine
02
Targets
MenACWY (Capsular polysaccharides of Neisseria meningitidis serogroups A, C, W, and Y)fHbp (Factor H-binding protein)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal groups A, B, C, W and Y vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal groups A, B, C, W and Y vaccine.